Results 11 to 20 of about 3,206 (156)
CIK Cells and HDAC Inhibitors in Multiple Myeloma. [PDF]
Int J Mol Sci, 2017 Multiple myeloma is the second most common hematological malignancy. Despite all the progress made in treating multiple myeloma, it still remains an incurable disease. Patients are left with a median survival of 4–5 years. The combined treatment of multiple myeloma with histone deacetylase inhibitors and cytokine-induced killer cells provides a ...
Stephan D, Weiher H, Schmidt-Wolf IGH.
europepmc +6 more sources
CIK Cell Therapy for Solid Tumor [PDF]
Nano Biomedicine and Engineering, 2014 In recent years, the clinical trials on applying cytokine induced killer (CIK) cells to solid tumor therapy have been launched worldwide. CIK cells are a heterogeneous subset of ex-vivo expanded T lymphocytes, they present a mixed T-NK phenotype and are ...
Jingjing Zhang, Yao Yang, Hualin Fu
doaj +2 more sources
Cytokine Induced Killer (CIK) Cells Based Adoptive Immunotherapy
Journal of Gandaki Medical College, 2018 Cytokine induced killer (CIK) cells has been increasingly used in adoptive immunotherapy against various cancers and viral infections. This review summarizes the basic overview of CIK cells as a therapeutic immunocyte.
S Timalsena, P P Lamichhane
doaj +3 more sources
CD4+ T cells are required to improve the efficacy of CIK therapy in non-small cell lung cancer
Cell Death and Disease, 2022 Herein, Liu and colleagues show that CD4+ T cells in cytokine-induced killer (CIK) cells are required to enhance the clinical efficacy of CIK therapy. In addition, CD4+ T cells help via IL-17A production is critical to restoring the function of CD8+/CD3 ...
Shaochuan Liu +14 more
doaj +3 more sources
Researche Advances on CIK Cells and Their Clinical Use in Lung Cancer
Chinese Journal of Lung Cancer, 2011 As the leading cause of cancer-related death among human beings, lung cancer seriously threats peoples’ health all over the world. Cytokine-induced killer cells (CIK) is a new kind of adaptive immune cells characterized by its dramatic proliferation ...
Hu LUO, Xiangdong ZHOU
doaj +3 more sources
CD44v6 as innovative sarcoma target for CAR-redirected CIK cells. [PDF]
Oncoimmunology, 2018 Purpose of our study was to explore a new immunotherapy for high grade soft tissue sarcomas (STS) based on cytokine-induced killer cells (CIK) redirected with a chimeric antigen receptor (CAR) against the tumor-promoting antigen CD44v6. We aimed at generating bipotential killers, combining the CAR specificity with the intrinsic tumor-killing ability of
Leuci V +15 more
europepmc +6 more sources
Frontiers in Immunology, 2021 Cytokine-induced killer (CIK) cells are an ex vivo expanded heterogeneous cell population with an enriched NK-T phenotype (CD3+CD56+). Due to the convenient and relatively inexpensive expansion capability, together with low incidence of graft versus host
Xiaolong Wu +7 more
doaj +1 more source
Cytokine-induced killer (CIK) cells in cancer immunotherapy: report of the international registry on CIK cells (IRCC). [PDF]
J Cancer Res Clin Oncol, 2015 Cytokine-induced killer (CIK) cells represent an exceptional T cell population uniting a T cell and natural killer cell like phenotype in their terminally differentiated CD3(+)CD56(+) subset, which features non-MHC-restricted tumor-killing activity. CIK cells are expandable from peripheral blood mononuclear cells and mature following the addition of ...
Schmeel LC +3 more
europepmc +3 more sources
BMC Immunology, 2023 Background Dendritic Cell Cytokine-induced killer cell (DC-CIK) coculture treatment in cancer immunotherapy has been shown to be effective. However, the cost of DC- CIK therapy is prohibitive for many patients, and the lack of standard manufacturing ...
Yi-Yen Lee +8 more
doaj +1 more source
Phenotypic characterization and anticancer capacity of CD8+ cytokine-induced killer cells after antigen-induced expansion. [PDF]
PLoS ONE, 2017 Cytokine-induced killer cells (CIK) have been used in clinic for adoptive immunotherapy in a variety of malignant tumors and have improved the prognosis of cancer patients.
Jianhua Liu +4 more
doaj +1 more source